Expansion of Proprietary Biopharmaceutical Platform Technology
First written in FY2016. 20 of 24 entries say "Advanced", first in FY2017-Q2. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「We are focusing on creating new platform technologies to follow J-Brain Cargo®. As one result, we created JUST-AAV, a new gene therapy technology using adeno-associated virus vectors. In addition to enabling efficient delivery of vectors to specific tissues, it is expected to reduce side effects by lowering vector accumulation in the liver, and development is proceeding as a new platform technology.」
For JUST-AAV, the company is advancing technological innovation to enhance muscle targeting in addition to brain targeting and reduce liver targeting, making its development as a new platform technology more concrete. - FY2025AdvancedAnnual report
「As one result, we created JUST-AAV, a new gene therapy technology using adeno-associated virus vectors. In addition to enabling efficient delivery of vectors to the brain, it is expected to reduce side effects by lowering vector accumulation in the liver, and development is proceeding as a new platform technology.」
The scope of the proprietary platform technology expanded from drug delivery using conventional J-Brain Cargo® to JUST-AAV, an AAV gene therapy technology designed to target the brain and reduce accumulation in the liver. - FY2025-H1AdvancedAnnual report
「In addition to research aimed at broadening the applicability of JCR's proprietary blood-brain barrier-penetrating technology, J-Brain Cargo®, to various modalities, we are focusing on creating new platform technologies to follow J-Brain Cargo®. As one result, in May 2024 we announced a new gene therapy technology using J-Brain Cargo® technology.」
The proprietary platform technology was expanded with the announcement in May 2024 of a new gene therapy technology applying J-Brain Cargo® to AAV, which is being developed as a new platform technology. - FY2024AdvancedAnnual report
「During the year, research using model mice confirmed that a drug incorporating J-Brain Cargo® crossed the blood-retinal barrier in mucopolysaccharidosis type II, became localized in the retina and reduced the disease-causing substance. The research indicated that this could improve visual impairment. In mucopolysaccharidosis type I, research using model mice likewise showed that a drug incorporating J-Brain Cargo® could suppress disease-specific morphological changes in bone.」
The scope of J-Brain Cargo® expanded beyond the brain. In mucopolysaccharidosis type II, model-mouse research demonstrated retinal delivery and a reduction in the disease-causing substance, while in mucopolysaccharidosis type I it demonstrated the potential to suppress morphological changes in bone. - FY2024-Q3AdvancedAnnual report
「In addition to research aimed at broadening the applicability of JCR's proprietary blood-brain barrier-penetrating technology, J-Brain Cargo®, to various modalities, we are focusing on creating new platform technologies to follow J-Brain Cargo®. In December 2023, we entered into a collaborative research, option and licence agreement with Alexion AstraZeneca Rare Disease (Alexion) to create novel nucleic acid medicines using J-Brain Cargo® technology.」
The scope of the proprietary platform technology expanded specifically to the creation of nucleic acid medicines, and a commercialization framework was added through a collaborative research, option and licence agreement with Alexion. - FY2024-Q1AdvancedAnnual report
「In addition to research aimed at broadening the applicability of JCR's proprietary blood-brain barrier-penetrating technology, J-Brain Cargo®, to various modalities, we are focusing on creating new platform technologies to follow J-Brain Cargo®.」
In addition to the policy of expanding J-Brain Cargo® into various modalities, the company entered into an exclusive global development and commercialization agreement with Angelini Pharma for a novel biologic treatment for epilepsy, making the application and commercialization of the technology more concrete. - FY2023AdvancedAnnual report
「J-Brain Cargo® has a wide range of variants, enabling selection of the optimal molecule for the characteristics of each drug. By applying protein engineering, we can create biopharmaceuticals with optimized binding affinity to receptors. Building on the utility of J-Brain Cargo® as a platform technology, we are working to create new platform technologies capable of delivering various modalities, including proteins, nucleic acids, gene and cell therapies, and antibodies, to organs other than the brain, such as the eyes, skeletal muscle and cartilage.」
The stated direction is to expand the scope of the proprietary technology from a focus on the brain and lysosomal diseases to organs such as the eyes, skeletal muscle and cartilage, as well as modalities including proteins, nucleic acids, gene and cell therapies, and antibodies. - FY2022AdvancedAnnual report
「J-Brain Cargo® is a technology capable of delivering drugs to the brain and various other tissues, and is being considered for application to a wide range of diseases in addition to lysosomal diseases.」
Based on knowledge gained through Izcargo® in clinical practice, the company gave concrete form to the optimization and application of J-Brain Cargo® across diverse modalities, including nucleic acids and proteins. Its application to treatments for more than 17 lysosomal diseases was also disclosed. - FY2021AdvancedAnnual report
「We have newly established a Translational Research Promotion Unit within our research division to advance basic research into technologies capable of efficiently delivering low- to mid-molecular-weight compounds, such as small molecules and nucleic acids, to the brain, create new platform technologies that can be out-licensed to other companies, and establish stable sources of revenue.」
A specific framework was established to advance basic research through a new unit within the research division focused on brain-delivery technologies for small molecules, nucleic acids and other compounds, complementing the existing application range of J-Brain Cargo®. - FY2020AdvancedAnnual report
「To explore these possibilities, we will advance basic research to develop technologies capable of efficiently delivering low- to mid-molecular-weight compounds, such as small molecules and nucleic acids, to the brain.」
Basic research to expand the existing application range of J-Brain Cargo® to low- to mid-molecular-weight compounds, such as small molecules and nucleic acids, beyond antibodies was newly prioritized. - FY2020-Q1RestatedAnnual report
「In addition, in terms of technology, the company established manufacturing technology for gene therapy products and will promote the development of new drugs and expansion of its licensing business together with its blood-brain barrier-penetrating technology, J-Brain Cargo®.」
The company reconfirmed its policy of leveraging its proprietary technology platform, including manufacturing technologies for gene therapy medicines in addition to recombinant medicines and regenerative medicine products. - FY2019AdvancedAnnual report
「In addition to the breakthrough technology J-Brain Cargo®, we have become a globally rare company with core technologies for the research, development and manufacture of products using three biotechnologies: recombinant medicines, regenerative medicine products and gene therapy medicines.」
The company explained that it had established manufacturing technologies for gene therapy medicines in addition to its existing recombinant medicines and regenerative medicine products, expanding the scope of its core technologies. - FY2019-Q2AdvancedAnnual report
「JR-441 (blood-brain barrier-penetrating recombinant heparan N-sulfatase) — Preclinical — Enzyme replacement therapy for Sanfilippo syndrome type A (lysosomal disease) — J-Brain Cargo® adopted — J-MIG System® adopted」
JR-441 was disclosed as a preclinical development product using J-Brain Cargo® and J-MIG System®, expanding the range of applications for the proprietary technologies. - FY2018AdvancedAnnual report
「JR-162 (recombinant acid α-glucosidase using J-Brain Cargo®) — Pompe disease (lysosomal disease) — Preclinical — J-Brain Cargo® adopted — J-MIG System® CHO cell high-expression technology adopted」
The company disclosed that J-Brain Cargo® and J-MIG System® have been adopted for JR-162, and that J-MIG System® has also been adopted for JR-142, as part of the application of its proprietary technologies. - FY2018-Q2AdvancedAnnual report
「JR-171 (recombinant α-L-iduronidase using J-Brain Cargo®) / J-Brain Cargo® adopted」
Application of the proprietary blood-brain barrier-penetrating technology to JR-171 was disclosed in addition to JR-141 and JR-162. - FY2017-Q2AdvancedAnnual report
「J-GlycoM® glycan-control technology adopted / J-MIG System® CHO cell high-expression technology adopted」
The company disclosed that J-GlycoM® has been adopted for JR-101 and J-MIG System® for JR-142, giving concrete form to the application of its proprietary technologies to development products. - FY2016First statedAnnual report
「We have also established various proprietary technologies, including technology to extend the duration of biopharmaceutical efficacy, J-Mab System®, which enables the efficient generation of highly functional antibodies, J-MIG System®, an efficient recombinant protein production technology, and the glycan-control technologies J-GlycoM® and J-GlycoS®.」
In addition to J-Brain Cargo®, the company has established multiple technologies for extending duration of action, antibody generation, protein production and glycan control, and is incorporating them into product development.